The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...

Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib ... improved from 15.2 months with standard chemotherapy, with or without bevacizumab, to 23.9 ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...